Donitriptan (; developmental code name F-11356) is a triptan drug which was investigated as an antimigraine agent but was never marketed. It acts as a selective serotonin 5-HT1B and 5-HT1D receptor agonist. The drug reached phase 2 prior to the discontinuation of its development.
Pharmacology
| + |
|
12–25 (Ki) 182–1,150 () |
0.08–0.36 (Ki) 0.10–1.8 () 94–100% () |
0.06–0.48 (Ki) 0.27–0.83 () 97–99% () |
1,150–1,700 (Ki) >10,000 () |
3,390–6,610 (Ki) >10,000 () |
182–447 (Ki) 7.9 () |
813 (Ki) 25 () |
575 (Ki) (rat) () |
| >10,000 (mouse) |
| 2,000 (guinea pig) |
| 813 |
| 2,340 |
372–617 (Ki) 5,890 () |
| |
| |
| |
| >10,000 |
| >10,000 |
| |
| >10,000 |
| >10,000 |
| |
| |
| >10,000 |
| >1,000 |
| |
| |
| >1,000 () |
| >1,000 () |
| >1,000 () |
| >10,000 |
| >10,000 |
|
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: |
Donitriptan acts as a high-affinity, high-efficacy near-full agonist of the serotonin 5-HT1B (Ki = 0.079–0.40nM; = 94%) and 5-HT1D receptors (Ki = 0.063–0.50nM; = 97%), and is among the most potent of the triptan series of drugs. It is also notable and unique among most of the triptans in being a potent serotonin 5-HT2A receptor agonist ( = 7.9nM), albeit with about one or two orders of magnitude lower activational potency than at the serotonin 5-HT1B and 5-HT1D receptors.
Chemistry
Donitriptan is a tryptamine derivative, a 5-substituted derivative of
tryptamine and 5-methoxytryptamine, and an analogue of the
dimethyltryptamine (DMT) and 5-MeO-DMT.
The predicted log P of donitriptan is 1.32 to 2.2.
History
Donitriptan was being developed in
France by bioMérieux-Pierre Fabre and made it to phase II
in
Europe before development was discontinued.
See also